Search Results 21-30 of 14170 for anti-TNF drugs

1. A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy - Mayo Clinic

   Drugs & Supplements A-Z · Health Books · Healthy Living Program · Mayo Clinic Health ... anti-tumor necrosis factor (TNF) therapy. Participation eligibility.

2. Inflammatory Bowel Disease (IBD) Clinical Trials - Mayo Clinic Research

   The purpose of this study is to determine whether adding low dose methotrexate to anti -TNF therapy is more effective than treatment with anti-TNF therapy alone ...

3. A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy - Mayo Clinic

   * Must have failed anti-TNF treatment for HS. * To be eligible for the Sub-study, participants must be naïve to biologic therapy for treatment of HS.

4. Ankylosing spondylitis - Diagnosis & treatment - Mayo Clinic

   If nonsteroidal anti-inflammatory drugs (NSAIDs) aren't helpful, your doctor might suggest starting a tumor necrosis factor (TNF) blocker or an interleukin-17 ( ...

5. Tofacitinib is first oral medication approved for use in treating moderate to severe ulcerative colitis - Mayo Clinic

   "It also appears to be efficacious in both the anti-TNF-exposed and anti-TNF-naive populations. So this will be a welcome addition to our armamentarium of ...

6. A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T) - Mayo Clinic

   ... treatment with anti-TNF-alpha agents. Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous ...

7. Head-to-head comparison between vedolizumab and adalimumab for treatment of moderately to severely active ulcerative colitis - Mayo Clinic

   The Food and Drug Administration approved the use of anti-tumor necrosis factor and anti-integrin agents for the treatment of ulcerative colitis in 2005 ...

8. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy - Mayo Clinic

   ... Anti-TNF Therapy. Print details. Share; Facebook · Twitter. Overview; Participation eligibility; Participating Mayo Clinic info; More information. Overview. Tab ...

9. Inflammatory bowel disease (IBD) - Diagnosis and treatment - Mayo Clinic

   Some are administered via intravenous (IV) infusions and others are injections you give yourself. Examples include infliximab (Remicade), adalimumab (Humira), ...

10. Sacroiliitis - Diagnosis and treatment - Mayo Clinic

    Tumor necrosis factor (TNF) inhibitors include etanercept (Enbrel), adalimumab (Humira), infliximab (Remicade) and golimumab (Simponi). Both types of ...